Thrombolytic therapy for acute ischaemic stroke.
Recombinant tissue plasminogen activator (rt-PA, also known as alteplase; Actilyse) is the first and only licensed thrombolytic approved for use in acute ischaemic stroke in the UK. This article reviews the evidence for the role of rt-PA in acute stroke management and how it may improve long-term clinical outcome for selected patients as part of a comprehensive stroke service.
Jenkinson
Damian
D
Royal Bournemouth and Christchurch Hospitals NHS Trust, Christchurch BH23 2JX.
D000208:Acute Disease; D002545:Brain Ischemia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D011364:Professional Practice; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator